The clinical effect of tigecycline combined with cefoperazone sulbactam in the treatment of muitidrug-resistant acinetobacter baumannii pneumonia
10.3969/j.issn.1006-5725.2015.05.040
- VernacularTitle:替加环素联合头孢哌酮舒巴坦治疗多重耐药鲍曼不动杆菌肺炎的疗效观察
- Author:
Yang ZHOU
;
He HUANG
;
Jiahong ZHANG
- Publication Type:Journal Article
- Keywords:
Cefoperazone sulbactam;
Tigecycline;
Muitidrug-resistant;
Acinetobacter baumannii;
Pneumonia
- From:
The Journal of Practical Medicine
2015;(5):816-818
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of tigecycline combined with cefoperazone sulbactam for the treatment of pneumonia caused by muitidrug-resistant acinetobacter baumannii pneumonia. Methods 68 patients with muitidrug-resistant acinetobacter baumannii pneumonia were randomly divided into two groups, control group and observation group, with 34 patients in each group. The control group was treated with cefoperazone sulbactam, and the observation group was treated with tigecycline combined with cefoperazone sulbactam. The level of PCT, CRP, WBC and clinical cure rates, as well as microbiological eradication and side effect, before and after treatment were collected and compared. Results After treatment, the level of PCT, WBC and CRP in two groups was decreased, and the observation group was more significant than the control group(P < 0.05). The side effect rate in two groups were 14.7% and 17.6% respectively (P > 0.05), while the clinical cure rates and microbiological eradication in observation group were significantly higher than the control group (P<0.05). Conclusion With a higher rate of clinical efficacy and a lower rate of side effect, the combination treatment with tigecycline and cefoperazone sulbactam would be a promising alternative for the treatment of muitidrug-resistant acinetobacter baumannii pneumonia infection.
